BRPI0315735A8 - método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico - Google Patents
método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico Download PDFInfo
- Publication number
- BRPI0315735A8 BRPI0315735A8 BRPI0315735A BR0315735A BRPI0315735A8 BR PI0315735 A8 BRPI0315735 A8 BR PI0315735A8 BR PI0315735 A BRPI0315735 A BR PI0315735A BR 0315735 A BR0315735 A BR 0315735A BR PI0315735 A8 BRPI0315735 A8 BR PI0315735A8
- Authority
- BR
- Brazil
- Prior art keywords
- breast cancer
- ngf
- diagnosis
- therapeutic use
- vitro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/48—Nerve growth factor [NGF]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
"método para o ensaio de ngf para a diagnose in vitro de câncer de mama e uso terapêutico". a presente invenção refere-se a um método para a diagnose in vitro de câncer de mama, o qual consiste em determinar a presença de ngf em uma amostra biológica derivada de um paciente suspeito de sofrer de câncer de mama. o dito método pode ser usado tanto em diagnose precoce, exame, acompanhamento terapêutico e prognóstico, quanto na diagnose de recorrência no caso de câncer de mama. a presente invenção também diz respeito ao uso de um par para ligação ao ngf ou de um inibidor do ngf para preparar um produto medicinal, o dito produto medicinal sendo, em particular, útil para bloquear a proliferação do tumor e a disseminação distante em pacientes sofrendo de câncer de mama. aplicações: diagnose e terapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0213428A FR2846426B1 (fr) | 2002-10-28 | 2002-10-28 | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
| PCT/FR2003/003193 WO2004040312A2 (fr) | 2002-10-28 | 2003-10-28 | Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR0315735A BR0315735A (pt) | 2005-09-06 |
| BRPI0315735A8 true BRPI0315735A8 (pt) | 2018-09-18 |
| BRPI0315735B1 BRPI0315735B1 (pt) | 2018-10-30 |
| BRPI0315735B8 BRPI0315735B8 (pt) | 2021-05-25 |
Family
ID=32088308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0315735A BRPI0315735B8 (pt) | 2002-10-28 | 2003-10-28 | método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7618790B2 (pt) |
| EP (2) | EP2085783A1 (pt) |
| JP (1) | JP4619125B2 (pt) |
| AT (1) | ATE426813T1 (pt) |
| AU (1) | AU2003285472B2 (pt) |
| BR (1) | BRPI0315735B8 (pt) |
| DE (1) | DE60326871D1 (pt) |
| ES (1) | ES2324818T3 (pt) |
| FR (1) | FR2846426B1 (pt) |
| WO (1) | WO2004040312A2 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4587281B2 (ja) * | 2004-06-21 | 2010-11-24 | 則男 長尾 | 癌転移抑制能測定する方法およびその測定器 |
| FR2896881B1 (fr) * | 2006-01-31 | 2008-04-18 | Biomerieux Sa | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
| WO2009149328A2 (en) * | 2008-06-05 | 2009-12-10 | The Administrators Of The Tulane Educational Fund | Methods and instrumentation for during-synthesis monitoring of polymer functional evolution |
| US9487582B2 (en) * | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| NZ611076A (en) | 2010-12-01 | 2015-09-25 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| JP7467866B2 (ja) * | 2019-10-02 | 2024-04-16 | 住友ゴム工業株式会社 | 親水性基材及び親水性基材作製方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2607507B1 (fr) | 1986-12-02 | 1990-04-13 | Centre Nat Rech Scient | Nouveaux derives a-d-oligonucleotides, leur preparation et leur emploi |
| WO1994006935A1 (en) * | 1992-09-11 | 1994-03-31 | Cephalon, Inc. | A method for the detection and treatment of prostate disease |
| FR2710075B1 (fr) | 1993-09-15 | 1995-10-27 | Bio Merieux | Réactif et procédé pour la détection d'une séquence nucléotidique avec amplification de signal. |
| US5475110A (en) * | 1994-10-14 | 1995-12-12 | Cephalon, Inc. | Fused Pyrrolocarbazoles |
| WO1997038313A1 (en) * | 1996-04-05 | 1997-10-16 | The Johns Hopkins University | A method of enriching rare cells |
| US20030104364A1 (en) * | 1997-06-25 | 2003-06-05 | Patricia A. Billing-Medel | Reagents and methods useful for detecting diseases of the breast |
| US6008003A (en) * | 1997-10-28 | 1999-12-28 | Promega Corporation | Non-invasive diagnostic method for interstitial cystitis and bladder cancer |
| FR2781802B1 (fr) | 1998-07-31 | 2001-05-11 | Bio Merieux | Derives satures ou insatures de l'abietane, conjugues derives et utilisations dans une composition diagnostique, un reactif et un dispositif |
| KR100740761B1 (ko) * | 2000-02-25 | 2007-07-19 | 옥스포드 글리코사이언시스(유케이) 리미티드 | 단백질 |
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| AU2002323151A1 (en) * | 2001-08-13 | 2003-03-03 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| US20050079557A1 (en) | 2002-03-13 | 2005-04-14 | Bio Merieux | Method for the detection and/or characterisation of circulating tumour cells and the use thereof in the early diagnosis, prognosis and diagnosis of relapses and in the selection and evaluation of therapeutic treatments |
-
2002
- 2002-10-28 FR FR0213428A patent/FR2846426B1/fr not_active Expired - Fee Related
-
2003
- 2003-10-28 EP EP09003850A patent/EP2085783A1/fr not_active Withdrawn
- 2003-10-28 JP JP2004547728A patent/JP4619125B2/ja not_active Expired - Lifetime
- 2003-10-28 EP EP03778473A patent/EP1556699B1/fr not_active Expired - Lifetime
- 2003-10-28 BR BRPI0315735A patent/BRPI0315735B8/pt not_active IP Right Cessation
- 2003-10-28 US US10/530,568 patent/US7618790B2/en not_active Expired - Lifetime
- 2003-10-28 WO PCT/FR2003/003193 patent/WO2004040312A2/fr not_active Ceased
- 2003-10-28 ES ES03778473T patent/ES2324818T3/es not_active Expired - Lifetime
- 2003-10-28 DE DE60326871T patent/DE60326871D1/de not_active Expired - Lifetime
- 2003-10-28 AU AU2003285472A patent/AU2003285472B2/en not_active Expired
- 2003-10-28 AT AT03778473T patent/ATE426813T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2846426A1 (fr) | 2004-04-30 |
| US7618790B2 (en) | 2009-11-17 |
| JP4619125B2 (ja) | 2011-01-26 |
| FR2846426B1 (fr) | 2004-12-10 |
| ATE426813T1 (de) | 2009-04-15 |
| DE60326871D1 (de) | 2009-05-07 |
| ES2324818T3 (es) | 2009-08-17 |
| AU2003285472A1 (en) | 2004-05-25 |
| US20060051818A1 (en) | 2006-03-09 |
| WO2004040312A2 (fr) | 2004-05-13 |
| EP2085783A1 (fr) | 2009-08-05 |
| BRPI0315735B8 (pt) | 2021-05-25 |
| AU2003285472B2 (en) | 2009-10-08 |
| BR0315735A (pt) | 2005-09-06 |
| EP1556699B1 (fr) | 2009-03-25 |
| EP1556699A2 (fr) | 2005-07-27 |
| JP2006504101A (ja) | 2006-02-02 |
| WO2004040312A3 (fr) | 2004-06-17 |
| BRPI0315735B1 (pt) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0412725A (pt) | marcadores para detecção de cáncer gástrico | |
| EP1578923A4 (en) | SOLUBLE MIC POLYPEPTIDE AS A MARKER FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASES OR DISEASES | |
| EP1842065A4 (en) | METHODS OF DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS | |
| BR0110091A (pt) | Composições e processos para terapia e diagnóstico de câncer de mama | |
| WO2006091412A3 (en) | Adamts-7 as a biomarker for cancers of epithelial origin | |
| ATE229073T1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
| BRPI0315735B8 (pt) | método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico | |
| MX2009005941A (es) | Ensayos de diagnostico complementario para terapia de cancer. | |
| TR199903154T2 (xx) | Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler | |
| WO2023004083A3 (en) | Compositions and methods for detection of bile duct cancer | |
| WO2023004079A3 (en) | Compositions and methods for detection of liver cancer | |
| BRPI0412110A (pt) | genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos | |
| BRPI0503418A (pt) | prognóstico para malignidade hematológica | |
| EP1451552A4 (en) | FOR DETECTING DISORDERS OF BREAST SUITABLE REAGENTS AND METHODS | |
| Zhang et al. | Neutrophil elastase specific fluorescent probe for early diagnosis of thyroiditis via serum sample testing and fluorescence imaging | |
| Yousefi et al. | Quantum dot-based diabetic foot mapping for diagnosing osteomyelitis and Charcot neuroarthropathy | |
| BR0009573A (pt) | Composições e métodos para o tratamento e diagnose do câncer de mama | |
| WO2006124866A3 (en) | Free human serum ige immunoenzymetric assay and methods of use | |
| WO2023004080A3 (en) | Compositions and methods for detection of pancreatic cancer | |
| Blois et al. | Detection of occult metastatic melanoma by urine chromatography | |
| RU2254576C2 (ru) | Способ прогнозирования эффективности лечения больных раком молочной железы iii-iv стадий | |
| WO2023004077A3 (en) | Compositions and methods for detection of colorectal cancer | |
| ATE429440T1 (de) | Formen prostataspezifischer antigene und verfahren zu deren nachweis | |
| ATE498020T1 (de) | 5t4 rna in plasma und serum als marker für neoplastische erkrankungen | |
| RU2241987C2 (ru) | Способ определения распространенности патологического процесса при онкологических заболеваниях |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/10/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/10/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2798 DE 20-08-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |